Review: Physical chemistry of solid dispersions

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 12, 2009, Pages 1571-1586

  Janssens, Sandrien ^a   Van Den Mooter, Guy ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Carrier selection; Crystallization; Glass solution; Molecular mobility; Solid solubility; Supersaturation

Indexed keywords

DRUG CARRIER; ETRAVIRINE; EVEROLIMUS; GRISEOFULVIN; HYDROXYPROPYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE; ISOPTIN SR E; ITRACONAZOLE; LOPINAVIR PLUS RITONAVIR; NABILONE; NILVADIPINE; POVIDONE; TACROLIMUS; TROGLITAZONE; UNCLASSIFIED DRUG; VERAPAMIL;

CRYSTALLIZATION; DISPERSION; DRUG BIOAVAILABILITY; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; MOLECULAR DYNAMICS; PHASE SEPARATION; PHYSICAL CHEMISTRY; REVIEW; SOLID;

EID: 75749094421     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.61.12.0001     Document Type: Review

References (137)

1. Lipinsky C. Poor aqueous solubility: an industry wide problem in drug discovery. Am Pharm Rev 2002; 5: 82-85.
2. Amidon GL et al. Theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413-420.
3. Peeters J et al. Characterization of the interaction of 2-hydroxypropyl-beta-cyclodextrin with itraconazole at pH 2, 4 and 7. J Pharm Sci 2002; 91: 1414-1422.
4. Noyes AA, Whitney WR. The rate of dissolution of solid substances in their own solutions. J AmChemSoc 1897; 19: 930-934.
5. Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci 1971; 60: 1281-1302.
6. Ford JL. The current status of solid dispersions. Pharm Acta Helv 1986; 61: 69-88.
7. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 2000; 50: 47-60.
8. Vasconcelos T et al. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Disc Today 2007; 12: 1068-1075.
9. Serajuddin ATM. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 1999; 88: 1058-1066.
10. Craig DQM. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm 2002; 231: 131-144.
11. Van Eerdenbrugh B et al. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm 2008; 364: 64-75.
12. Mirza S et al. Co-crystals: an emerging approach for enhancing properties of pharmaceutical solids. Dosis 2008; 24: 90-96.
13. Cole ET et al. Challenges and opportunities in the encapsulation of liquid and semi-solid formulations into capsules for oral administration. Adv Drug Deliv Rev 2008; 60: 747-756.
14. Sekiguchi K, Obi N. Studies on absorption of eutectic mixture I. A comparison of the behaviour of eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem Pharm Bull 1961; 9: 866-872.
15. Doelker M et al. Hot extruded dosage forms. Pharm Acta Helv 1971; 46: 31-52.
16. Nakamichi K et al. New preparation method of solid dispersion by twin screw extruder. Pharm Tech Jpn 1996; 12: 715-729.
17. Zang F, McGinity JW. Properties of sustained-release tablets prepared by hot-melt extrusion. Pharm Dev Technol 1999; 4: 241-250.
18. Repka MA et al. Influence of plasticizers and drugs on the physical-mechanical properties of hydroxypropylcellulose films prepared by hot-melt extrusion. Drug Dev Ind Pharm 1999; 25: 625-633.
19. Repka MA, McGinity JW. Bioadhesive properties of hydroxypropylcellulose topical films produced by hot-melt extrusion. J Control Release 2001; 70: 341-351.
20. Aitken-Nichol C et al. Hot melt extrusion of acrylic films. Pharm Res 1996; 13: 804-808.
21. Kanig JL. Properties of fused mannitol in compressed tablets. J Pharm Sci 1964; 188-192.
22. Dittgen M et al. The use of sugar and sugar alcohols to enhance the solubility and the bioavailability of drugs. Eur J Pharm Biopharm 1994; 40: 14S
23. Dittgen M et al. Hot spin mixing: a new technology to manufacture solid dispersions, part 1: testosterone. Pharmazie 1995; 50: 225-226.
24. Dittgen M et al. Hot spin melting - a new technology to manufacture solid dispersions, part 3: progesterone. Pharmazie 1995; 50: 507-508.
25. Tejwani RW et al. Study of phase behavior of poly(ethylene glycol)-polysorbate 80-water mixtures. J Pharm Sci 1999; 89: 7.
26. Dannenfelser RM et al. Development of clinical dosage forms for a poorly water soluble drug I: Application of polyethylene glycol-polysorbate 80 solid dispersion carrier system. J Pharm Sci 2004; 93: 1165-1175.
27. Joshi HH et al. Bioavailability enhancement of a poorly water-soluble drug by solid dispersion in polyethylene glycolpolysorbate 80 mixture. Int J Pharm 2004; 269: 251-258.
28. Wulff M et al. An investigation into the critical surfactant concentration for solid solubility of hydrophobic drug in different polyethylene glycols. Int J Pharm 1996; 142: 189-198.
29. Goldberg AH et al. Increasing dissolution rates and gastrointestinal absorption of drugs via solid solutions and eutectic mixtures I: theoretical considerations and discussion of the literature. J Pharm Sci 1965; 54: 1145-1148.
30. El-Banna HM et al. Physicochemical study of drug binary systems. Part 3: Tolbutamide-urea and tolbutamide-mannitol systems. Pharmazie 1975; 30: 788-792.
31. Van den Mooter G et al. Physical stabilization of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur J Pharm Sci 2001; 23: 261-269.
32. Tachibana T, Nakamura N. Method for preparing an aqueous colloidal dispersion of organic materials by using water-soluble polymers: dispersion of beta-carotene by polyvinylpyrrolidone. Kolloid-Z Polym 1965; 203: 130-133.
33. Vehring R. Pharmaceutical particle engeneering via spray drying. Pharm Res 2007; 25: 999-1022.
34. Betageri GV, Makarla KR. Enhancement of dissolution of glyburide by solid dispersion and lyophilization techniques. Int J Pharm 1995; 216: 155-160.
35. Tang X, Pikal MJ. Design of freeze-drying processes for pharmaceuticals: practical advice. Pharm Res 2004; 21: 191-200.
36. Chuanbin W, McGinity JW. Influence of ibuprofen as a solid-state plasticizer in Eudragit RS 30 D on the physicochemical properties of coated beads. AAPS Pharm Sci Tech 2001; 1: 1-9.
37. Hsiu-O H, Huei-Lin S. The preparation and characterization of solid dispersions on pellets using a fluidized bed system. Int J Pharm 1996; 139: 223-229.
38. Kenawy ER et al. Release of tetracycline hydrochloride from electrospun poly(ethylene-co-vinyl acetate), poly(lactic acid), and a blend. J Control Release 2002; 81: 57-64.
39. Brewster ME et al. The use of polymer-based electrospun nanofibers containing amorphous drug dispersions for the delivery of poorly water-soluble pharmaceuticals. Pharmazie 2004; 59: 387-391.
40. Verreck G et al. The effect of pressurized carbon dioxide as a plasticizer and foaming agent on the hot melt extrusion process and extrudate properties of pharmaceutical polymers. J Supercrit Fluids 2005; 38: 383-391.
41. Verreck G et al. The effect of pressurized carbon dioxide as a temporary plasticizer and foaming agent on the hot stage extrusion process and extrudate properties of solid dispersions of itraconazole with PVP-VA 64. Eur J Pharm Sci 2005; 26: 349-358.
42. 2 as a reversible plasticizer and foaming agent on the hot stage extrusion of itraconazole with EC 20 cps. J Supercrit Fluids 2007; 40: 153-162.
43. 2 as a temporary plasticizer. Int J Pharm 2006; 327: 45-50.
44. Pasquali I et al. Supercritical fluid technologies: an innovative approach for manipulating the solid-state of pharmaceuticals. Adv Drug Deliv Rev 2008; 60: 399-410.
45. Karunakaran K. Theoretical prediction of eutectic temperature and composition. J Sol Chem 1981; 10: 431-435.
46. Findlay A. The Phase Rule and its Applications. New York: Dover publications Ltd, 1951.
47. Hume-Rotherly W. The Structure of Metals and Alloys. London: Institute of Metals, 1954.
48. Reed-Hill RE. Physical Metallurgy Principles. Princetown, NJ: D Van-Nostrand, 1964.
49. Schachter DM et al. Solid state NMR perspective of drugpolymer solid solutions: a model system based on poly(ethylene oxide). Int J Pharm 2004; 281: 89-101.
50. Yeh F et al. Effect of miscible polymer diluents on the development of lamellar morphology in poly(oxymethylene) blends. J Polymer Sci 1999; 37: 3115-3122.
51. 2 on phase structure of PEO/PVAc blends evaluated from SAXS absolute intensity measurement. Polymer 2002; 43: 3691-3698.
52. Dreezen G et al. Nano-structured polymer blends: phase structure, crystallization behaviour and semi-crystalline morphology of phase separated binary blends of poly(ethylene oxide) and poly (ether sulphone). Polymer 2000; 41: 1395-1407.
53. Van Drooge DJ et al. Incorporation of lipophilic drugs in sugar glasses by lyophilization using a mixture of water and tertiary butyl alcohol as solvent. J Pharm Sci 2003; 93: 713-725.
54. Van Drooge DJ et al. Anomalous dissolution of tablets prepared from sugar glass-based solid dispersions. J Control Release 2004; 97: 441-452.
55. Allen LV et al. Dissolution rates of corticosteroids utilizing sugar glass dispersions. J Pharm Sci 1977; 66: 494-497.
56. Simonelli AP et al. Dissolution rates of high energy polyvinylpyrrolidone (PVP)-saphathiazole coprecipitates. J Pharm Sci 1969; 58: 538-549.
57. Lindfors L et al. Nucleation and crystal growth in supersaturated solutions of model drug. J Colloid Interface Sci 2008; 325: 404-413.
58. Raghavan SL et al. Formation and stabilization of triclosan colloidal suspensions using supersaturated systems. Int J Pharm 2003; 261: 153-158.
59. Raghavan SL et al. Crystallization of hydrocortisone acetate: influence of polymers. Int J Pharm 2001; 212: 213-221.
60. Dressman JB et al. Estimating drug solubility in the gastrointestinal tract. Adv Drug Deliv Rev 2007; 59: 591-602.
61. Clarysse S et al. Postprandial changes in solubilizing properties of human intestinal fluids. AAPS J 2007; 9(S2): Abstract T3150.
62. Six K et al. Thermal properties of hot-stage extrudates of itraconazole and eudragit E100. J Therm An Cal 2002; 68: 591-601.
63. Six K et al. Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion, part II. Pharm Res 2003; 20: 1047-1054.
64. Six K et al. Increased physical stability and improved dissolution properties of itraconazole, a class II drug, by solid dispersions that combine fast- and slow- dissolving polymers. J Pharm Sci 2004; 93: 124-131.
65. Janssens S et al. Physical stability of ternary solid dispersions of itraconazole in polyethyleneglycol 6000 / hydroxypropyl-methylcellulose 2910 E5 blends. Int J Pharm 2008; 355: 100-107.
66. Chawla G, Bansal AK. A comparative assessment of solubility advantage from glassy and crystalline forms of a water-insoluble drug. Eur J Pharm Sci 2007; 32: 45-57.
67. Bhugra C, Pikal MJ. Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state. J Pharm Sci 2007; 97: 1329-1349.
68. Marsac PJ et al. Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. Pharm Res 2006; 23: 2417-2426.
69. Yoshioka M et al. Crystallization of indomethacin from the amorphous state below and above its glass transition temperature. J Pharm Sci 1994; 83: 1700-1705.
70. Gordon S, Taylor JS. Ideal copolymers and the second-order transitions of synthetic rubbers. I. Non-crystalline copolymers. J Appl Chem 1952; 2: 493-500.
71. Kelley FN, Bueche F. Viscosity and glass temperature relations for polymer-diluent systems. J Polym Sci 1961; 50: 549-556.
72. Simha R, Boyer RF. General relation involving the glass transition temperature and coefficient of expansion of polymers. J Chem Phys 1962; 37: 1003-1007.
73. Ito K et al. Thermodynamic determination of fragility in liquids and a fragile-to-strong liquid transition in water. Nature 1999; 398: 492-495.
74. Taylor LS et al. Fourier transform raman spectroscopic study of the interaction of water vapour with amorphous polymers. J Pharm Sci 2001; 90: 888-891.
75. Hancock BC, Zografi G. The use of solution theories for predicting water vapour adsorption by amorphous pharmaceutical solids. Pharm Res 1993; 10: 1262-1267.
76. Zhang J, Zografi G. The relationship between BET and free volume derived parameters for water vapour adsorption into amorphous solids. J Pharm Sci 2000; 89: 1063-1072.
77. Oksanen CA, Zografi G. Molecular mobility in mixtures of adsorbed water and solid poly(vinyl-pyrrolidone). Pharm Res 1993; 10: 791-799.
78. Shamblin S, Zografi G. The effects of adsorbed water on the properties of amorphous mixtures containing sucrose. Pharm Res 1999; 16: 1119-1124.
79. Fox TG. Influence of diluent and of copolymer composition on the glass transition temperature of a polymer system. Bull Am Phys Soc 1956; 1: 123.
80. Couchman PR, Karasz FE. A classical thermodynamic discussion on the effect of composition on glass-transition temperatures. Macromolecules 1978; 11: 117-119.
81. Pinal R. Entropy of mixing and the glass transition of amorphous mixtures. Entropy 2008; 10: 207-223.
82. Matsumoto T, Zografi G. Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinyl-acetate) in relation to indomethacin recrystallization. Pharm Res 1999; 16: 1722-1728.
83. Six K et al. Clinical study of solid dispersions of itraconazole prepared by hot-stage extrusion. Eur J Pharm Sci 2005; 24: 179-186.
84. Corrigan OI. Retardation of polymeric carrier dissolution by dispersed drugs: factors influencing the dissolution of solid dispersions containing polyethylene glycols. Drug Dev Ind Pharm 1986; 12: 1777-1793.
85. Rodriguez-Hornedo N, Murphy D. Significance of controlling crystallization mechanisms and kinetics in pharmaceutical systems. J Pharm Sci 1999; 88: 651-666.
86. Zhuang H, Mao C. Understanding of polymers on enhancing solution concentration of poorly soluble drugs in super-saturated systems. AAPS J 2006; 8: Abstract W4228.
87. Guzman HR et al. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci 2007; 96: 2686-2702.
88. Overhoff KA et al. Effect of stabilizer on the maximum degree and extent of supersaturation and oral absorption of tacrolimus made by ultra-rapid freezing. Pharm Res 2008; 25: 167-175.
89. Kostewicz ES et al. Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine. J Pharm Pharmacol 2004; 56: 43-51.
90. Kashchiev D, Van Rosmalen GM. Review: nucleation in solutions revisited. Cryst Res Technol 2003; 38: 555-574.
91. Miller J et al. Solvent systems for crystallization and polymorph selection. In: Augustijns P, Brewster M. eds. Solvent Systems and their Selection in Pharmaceutics and Biopharmaceutics. New York: Springer and AAPS Press, 2007; 53-110.
92. Vandecruys R et al. Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design. Int J Pharm 2007; 342: 168-175.
93. Janssens S et al. Formulation and characterization of ternary solid dispersions made up of itraconazole and two excipients, TPGS 1000 andPVPVA64, thatwere selected based on a supersaturation screening study. Eur J Pharm Biopharm 2008; 69: 158-166.
94. Simonelli AP et al. Inhibition of sulfathiazole crystal growth by polyvinylpyrrolidone. J Pharm Sci 1970; 59: 633-638.
95. Terayama H et al. Preparation of stable aqueous suspension of a hydrophobic drug with polymers. Colloids Surf B Biointerfaces 2004; 39: 159-164.
96. Brouwers J et al. Supersaturating drug delivery systems: the answer to solubility limited oral bioavailability? J Pharm Sci 2009; 98: 2549-2572.
97. Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 1997; 86: 1-12.
98. Yu L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv Rev 2001; 48: 27-42.
99. Willart JF, Descamps M. Solid state amorphization of pharmaceuticals. Mol Pharm 2008; 5: 905-920.
100. Mao C et al. Time-dependence of molecular mobility during structural relaxation and its impact on organic armophous solids: an investigation based on a calorimetric approach. Pharm Res 2006; 23: 1906-1916.
101. Hancock BC et al. Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm Res 1995; 12: 799-806.
102. Hancock BC, Shamblin SL. Molecular mobility of amorphous pharmaceuticals determined using differential scanning calorimetry. Thermochim Acta 2001; 380: 95-107.
103. Monserrat S. Physical aging studies in epoxy resins. I. Kinetics of the enthalpy relaxation process in a fully cured epoxy resin. J Polym Sci B 1994; 32: 509-522.
104. Van den Mooter G et al. Stability prediction of amorphous benzodiazepines by calculation of the mean relaxation time constant using the William-Watts decay function. Eur J Pharm Biopharm 1998; 48: 43-48.
105. SixKet al.Characterization of glassy itraconazole: a comparative study of its molecular mobility below Tg with that of structural analogues using MTDSC. Int J Pharm 2001; 213: 163-173.
106. Kakumanu VK, Bansal A. Enthalpy relaxation studies of celecoxib amorphous mixtures. PharmRes 2002; 19: 1873-1878.
107. Marsac PJ et al. A comparison of the physical stability of amorphous felodipine and nifedipine systems. Pharm Res 2006; 23: 2306-2316.
108. Liu J et al. Dynamics of pharmaceutical amorphous solids: the study of enthalpy relaxation by isothermal microcalorimetry. J Pharm Sci 2002; 91: 1853-1862.
109. Mao C et al. A calorimetric method to estimate molecular mobility of amorphous solids at relatively low temperatures. Pharm Res 2006; 23: 2269-2276.
110. Adam G, Gibbs JH. On temperature dependence of cooperative relaxation properties in glass-forming liquids. J Chem Phys 1965; 43: 139-146.
111. Crowly KJ, Zografi G. The use of thermal methods for predicting glass-former fragility. Thermochim Acta 2001; 380: 79-93.
112. Moynihan CT et al. Dependence of glass-transition temperature on heating and cooling rate. J Phys Chem1974; 78: 2673-2677.
113. Andronis V, Zografi G. The molecular mobility of supercooled amorphous indomethacin as a function of temperature and relative humidity. Pharm Res 1998; 15: 835-842.
114. Hodge IM. Strong and fragile liquids: a brief critique. J Non-Cryst Solids 1996; 202: 164-172.
115. Descamps N et al. The amorphous state of spray-dried maltodextrin: sub-sub-Tg enthalpy relaxation and impact of temperature and water annealing. Carbohydr Res 2009; 344: 85-90.
116. Alie J et al. Dielectric study of the molecular mobility and the isothermal crystallization kinetics of an amorphous pharmaceutical drug substance. J Pharm Sci 2004; 93: 218-231.
117. Correia NLT et al. Molecular mobility and fragility in indomethacin: a thermally stimulated depolarization current study. Pharm Res 2001; 18: 1767-1774.
118. Hikima T et al. Microscopic observation of a peculiar crystallization in the glass transition region and beta process as potentially controlling the growth rate in triphenylethylene. J Mol Struct 1999; 479: 245-250.
119. Bhattacharya S, Suryanarayanan R. Local mobility in amorphous pharmaceuticals - characterization and implications on stability. J Pharm Sci 2009; 98: 2935-2953.
120. Yoshioka S et al. The effect of excipients on the molecular mobility of lyophilized formulations, as measured by glass transition temperature and NMR relaxation-based critical mobility temperature. Pharm Res 1999; 16: 135-140.
121. Suihko EJ et al. A solid-state NMR study of molecular mobility and phase separation in co-spray-dried protein-sugar particles. Eur J Pharm Sci 2005; 25: 105-112.
122. Masuda K et al. Comparison of molecular mobility in the glassy state between amorphous indomethacin and salicin based on spin-lattice relaxation times. Pharm Res 2005; 22: 797-805.
123. James PF. Kinetics of crystal nucleation in silicate glasses. J Non-Cryst Solids 1985; 73: 517-540.
124. Turnbull D, Fisher JC. Rate of nucleation in condensed systems. J Chem Phys 1949; 17: 71-73.
125. Zhou DL et al. Physical stability of amorphous pharmaceuticals: importance of configurational thermodynamic quantities and molecular mobility. J Pharm Sci 2002; 91: 1863-1872.
126. Bhugra C et al. Prediction of the onset of crystallization of amorphous sucrose below the calorimetric glass transition temperature from correlations with mobility. J Pharm Sci 2007; 96: 1258-1268.
127. Bhugra C et al. Predictions of onset of crystallization from experimental relaxation times. I-correlation of molecular mobility from temperatures above the glass transition to temperatures below the glass transition. Pharm Res 2006; 23: 2277-2289.
128. Bhugra C et al. Prediction of onset of crystallization from experimental relaxation times. II. Comparison between predicted and experimental onset times. J Pharm Sci 2007; 97: 455-471.
129. Korhonen O et al. Correlation between molecular mobility and crystal growth of amorphous phenobarbital and phenobarbital with polyvinylpyrrolidone and l-proline. J Pharm Sci 2008; 97: 3830-3840.
130. Flory PJ. Principles of Polymer Chemistry. Ithaca: Cornell University Press, 1953.
131. Young RJ, Lovell PA. Introduction to Polymers. UK: Nelson Thornes, Cheltenham, 1991.
132. Rubinstein M, Colby RH. Polymer Physics. New York: Oxford University Press, 2003.
133. Wertheim MS. Fluids with highly directional attractive forces. I. Statistical thermodynamics. J Statistical Physics 1984; 35: 19-34.
134. Wertheim MS. Fluids with highly directional attractive forces. II. Thermodynamic perturbation theory and integral equations. J Statistical Physics 1984; 35: 35-47.
135. Vasanthavada M et al. Phase behavior of amorphous molecular dispersions I: Determination of the degree and mechanism of solid solubility. Pharm Res 2004; 21: 1598-1606.
136. Avrami M. Kinetics of phase change. I General theory. J Chem Phys 1939; 7: 1103-1112.
137. Avrami M. Kinetics of phase change. II transformation-time relations for random distribution of nuclei. J Chem Phys 1940; 8: 212-224.